Cytokinetics reiterated by JMP at market outperform

Cytokinetics, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating and a $13 price target after the company presented at a medical conference phase 2 results with ispinesib in previously treated metastatic breast cancer that showed encouraging anti-tumor activity and notable safety warranting further studies. The company has five promising clinical trials underway or starting soon and platform-validating data from substantive clinical trials expected over the next 12 months. Shares of the biopharmaceutical company were down 3 cents, or 0.38%, at $7.97 on volume of 132,988 shares versus the three-month running average of 102,392 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.